Journal Mobile Options
Table of Contents
Vol. 126, No. 1, 2011
Issue release date: June 2011
Acta Haematol 2011;126:13–20
(DOI:10.1159/000323661)

Expansion of CD56-Negative, CD16-Positive, KIR-Expressing Natural Killer Cells after T Cell-Depleted Haploidentical Hematopoietic Stem Cell Transplantation

De Angelis C. · Mancusi A. · Ruggeri L. · Capanni M. · Urbani E. · Velardi A. · Stern M.
aDivision of Hematology and Clinical Immunology, Department of Clinical and Experimental Medicine, University of Perugia, Perugia, Italy; bDivision of Hematology and Department of Biomedicine, University Hospital Basel, Basel, Switzerland

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

The main functions of natural killer (NK) cells are early protection against viruses or tumor cells and production of cytokines that regulate immune functions. The present study assessed the role of different NK subsets in exerting graft-versus-leukemia effects in recipients of human leukocyte antigen (HLA) haploidentical hematopoietic transplants and monitored for the first time CD3–/CD56– lymphocyte expansion. CD3–/CD56– cells expressed NK cell-associated molecules, such as CD16, NKp46, NKp30, CD244 (2B4), CD161, and killer cell immunoglobulin-like receptors. CD3–/CD56– cells further exhibited the classical functional characteristics of NK cells: cytolysis of target cells lacking HLA class I, antibody-dependent cellular cytotoxicity and cytokine production. These results demonstrate that CD56– NK cells are functional, recognize missing self and, like their CD56+ counterparts, may contribute to graft-versus-leukemia reactions.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Caligiuri MA: Human natural killer cells. Blood 2008;112:461–469.
  2. Cooper MA, Fehniger TA, Caligiuri MA: The biology of human natural killer-cell subsets. Trends Immunol 2001;22:633–640.
  3. Trinchieri G: Biology of natural killer cells. Adv Immunol 1989;47:187–376.
  4. Karre K: Immunology. A perfect mismatch. Science 2002;295:2029–2031.
  5. Ljunggren HG, Karre K: In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today 1990;11:237–244.
  6. Moretta L, Moretta A: Killer immunoglobulin-like receptors. Curr Opin Immunol 2004;16:626–633.
  7. Parham P: Taking license with natural killer cell maturation and repertoire development. Immunol Rev 2006;214:155–160.
  8. Ruggeri L, Aversa F, Martelli MF, Velardi A: Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self. Immunol Rev 2006;214:202–218.
  9. Velardi A, Ruggeri L, Moretta A, Moretta L: NK cells: a lesson from mismatched hematopoietic transplantation. Trends Immunol 2002;23:438–444.
  10. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S: Functions of natural killer cells. Nat Immunol 2008;9:503–510.
  11. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA: Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002;100:1935–1947.
  12. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, Urbani E, Negrin RS, Martelli MF, Velardi A: Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999;94:333–339.
  13. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097–2100.
  14. Ruggeri L, Mancusi A, Capanni M, Martelli MF, Velardi A: Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. Curr Opin Immunol 2005;17:211–217.
  15. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, Stern M, Pende D, Perruccio K, Burchielli E, Topini F, Bianchi E, Aversa F, Martelli MF, Velardi A: Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007;110:433–440.
  16. Velardi A, Ruggeri L, Mancusi A, Burchielli E, Perruccio K, Aversa F, Martelli MF: Clinical impact of natural killer cell reconstitution after allogeneic hematopoietic transplantation. Semin Immunopathol 2008;30:489–503.
  17. Alter G, Malenfant JM, Altfeld M: CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004;294:15–22.
  18. Eissens DN, Schaap NP, Preijers FW, Dolstra H, van Cranenbroek B, Schattenberg AV, Joosten I, van der Meer A: CD3(+)/CD19(+)-depleted grafts in HLA-matched allogeneic peripheral blood stem cell transplantation lead to early NK cell cytolytic responses and reduced inhibitory activity of NKG2A. Leukemia 2009.
  19. Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, Stewart CA, Breso V, Frassati C, Reviron D, Middleton D, Romagne F, Ugolini S, Vivier E: Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006;25:331–342.
  20. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA: Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001;97:3146–3151.
  21. Mavilio D, Lombardo G, Benjamin J, Kim D, Follman D, Marcenaro E, O’Shea MA, Kinter A, Kovacs C, Moretta A, Fauci AS: Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci U S A 2005;102:2886–2891.
  22. Mavilio D, Lombardo G, Kinter A, Fogli M, La Sala A, Ortolano S, Farschi A, Follmann D, Gregg R, Kovacs C, Marcenaro E, Pende D, Moretta A, Fauci AS: Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. J Exp Med 2006;203:2339–2350.
  23. Gonzalez VD, Falconer K, Bjorkstrom NK, Blom KG, Weiland O, Ljunggren HG, Alaeus A, Sandberg JK: Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment. J Immunol 2009;183:6612–6618.
  24. Zarife MA, Reis EA, Carmo TM, Lopes GB, Brandao EC, Silva HR, Santana N, Martins-Filho OA, Reis MG: Increased frequency of CD56Bright NK-cells, CD3-CD16+CD56- NK-cells and activated CD4+T-cells or B-cells in parallel with CD4+CDC25High T-cells control potentially viremia in blood donors with HCV. J Med Virol 2009;81:49–59.
  25. Vitelli-Avelar DM, Sathler-Avelar R, Dias JC, Pascoal VP, Teixeira-Carvalho A, Lage PS, Eloi-Santos SM, Correa-Oliveira R, Martins-Filho OA: Chagasic patients with indeterminate clinical form of the disease have high frequencies of circulating CD3+CD16–CD56+ natural killer T cells and CD4+ CD25 High regulatory T lymphocytes. Scand J Immunol 2005;62:297–308.
  26. Andersson S, Fauriat C, Malmberg JA, Ljunggren HG, Malmberg KM: KIR acquisition probabilities are independent of self-HLA class I ligands and increase with cellular KIR expression. Blood 2009;114:95–104.
  27. Yu J, Heller G, Chewning J, Kim S, Yokoyama WM, Hsu K: Hierarchy of the Human Natural Killer Cell Response Is Determined by Class and Quantity of Inhibitory Receptors for Self-HLA-B and HLA-C Ligands1. The Journal of Immunology 2007;179:5977–5989.
  28. Lu X, Kondo Y, Takamatsu H, Ohata K, Yamazaki H, Takami A, Akatsuka Y, Nakao S: CD16+ CD56- NK cells in the peripheral blood of cord blood transplant recipients: a unique subset of NK cells possibly associated with graft-versus-leukemia effect. Eur J Haematol 2008;81:18–25.
  29. Dunbar EM, Buzzeo MP, Levine JB, Schold JD, Meier-Kriesche HU, Reddy V: The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease. Haematologica 2008;93:1852–1858.
  30. Willemze R, Rodrigues CA, Labopin M, Sanz G, Michel G, Socie G, Rio B, Sirvent A, Renaud M, Madero L, Mohty M, Ferra C, Garnier F, Loiseau P, Garcia J, Lecchi L, Kogler G, Beguin Y, Navarrete C, Devos T, Ionescu I, Boudjedir K, Herr AL, Gluckman E, Rocha V: KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia 2009;23:492–500.
  31. Vago L, Forno B, Sormani MP, Crocchiolo R, Zino E, Di Terlizzi S, Lupo Stanghellini MT, Mazzi B, Perna SK, Bondanza A, Middleton D, Palini A, Bernardi M, Bacchetta R, Peccatori J, Rossini S, Roncarolo MG, Bordignon C, Bonini C, Ciceri F, Fleischhauer K: Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. Blood 2008;112:3488–3499.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50